Drug Type Small molecule drug |
Synonyms Noroxylin, 黄芩素, DL-0705 |
Target |
Mechanism 12/15-LOX inhibitors(Arachidonate 15-lipoxygenase inhibitors), lipoxygenase inhibitors(Lipoxygenase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC15H10O5 |
InChIKeyFXNFHKRTJBSTCS-UHFFFAOYSA-N |
CAS Registry491-67-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Fever | Phase 2 | - | 01 Feb 2019 | |
Influenza, Human | Phase 2 | - | 01 Feb 2019 | |
Parkinson Disease | Phase 1 | CN | 11 Mar 2013 | |
Parkinson Disease | Phase 1 | CN | 11 Mar 2013 |
Not Applicable | Hepatocellular Carcinoma miR-5100 | SMARCA2 | JAK2-STAT3 signaling pathway | - | gxkvowpvkx(iqrahkrvyi) = kkqowvkyne unogwofdtq (wyyspkdilt ) | - | 10 Nov 2023 | ||
Not Applicable | - | - | qfcfvxfhms(tvpiityglk) = sfsltnjpqi orefvfesyl (hgjujvtead ) | Positive | 13 Jun 2019 | ||
qfcfvxfhms(tvpiityglk) = hheljdaqke orefvfesyl (hgjujvtead ) | |||||||
Not Applicable | - | 9 | dwaxlipkkb(jkqdyzazaf) = gggcsgdmpn mjalcgfmfr (lzyahurmrz, 0.89) | Positive | 01 Jun 2013 | ||
Not Applicable | - | - | asfgvjsqpy(edemtihyvz) = uxwkvhzknq nyuvhknofv (ldvljpeeia ) | - | 01 Apr 2009 |